Is Sentinel Lymph Node Biopsy Necessary In Ductal Carcinoma In Situ?

Year 2017, Volume: 31 Issue: 3, 147 - 151, 17.12.2017

Süleyman Özkan Aksoy Ali İbrahim Sevinç Merih Güray Pınar Balcı

Abstract

Objective: Ductal carcinoma in situ (DCIS) is
a proliferation of mammary ductal epithelial cells that does not cross the
basal membrane and has no evidence of invasion. One of the recent arguments is
that a sentinel lymph node biopsy (SLNB) is required for high risk of invasive
disease in DCIS cases.

Material and method: We retrospectively reviewed SLNB results in a total
of 144 DCIS patients, 112 with microinvasive foci and 32 with mastectomy
indication between 1996 and 2016 in our clinic.

Results: The mean age of the patients was
53 (36-77) years. A total of 103 (71%) of the cases were treated with
wire-guided biopsy, 34 (24%) with wide local excision, and 7 (5%) with
subareolar exploration for histopathological diagnosis. Histopathological
examination showed no invasion of any sentinel lymph node specimen.
Radiotherapy and hormonotherapy were applied to patients with microinvasion and
only hormonotherapy was applied to the patients treated with mastectomy as
adjuvant therapy. There was no recurrence of axillary lesions in the average
follow-up of 48 months.

Conclusion: As axillary metastases were found
to be quite low (<1%) in DCIS, axillary lymph node sampling should not be
routinely performed in these patients. Axillary sampling may be done with SLNB
in DCIS patients with microinvasive foci or having mastectomy indication,
avoiding possible morbidity of axillary dissection.

Keywords

Ductal Carsinoma in Situ, Sentinel Lymph Node Biopsy, Breast Cancer

Duktal karsinoma in situ da sentinel lenf nodu biyopsisi gerekli midir?

Abstract

Amaç: Duktal karsinoma in situ (DKİS)
memede duktal epitelyum hücrelerinin bazal membranı aşmayan ve invazyon kanıtı olmayan
proliferasyonudur. Son tartışmalardan birisi de DKİS vakalarında yüksek invaziv
hastalık riski ile birlikte, sentinel lenf nodu biyopsisi (SLNB) gerekli olup
olmadığıdır.

Gereç ve yöntem: Kliniğimizde 1996-2016 yılları
arasında 112 mikroinvaziv odaklı ve 32 mastektomi endikasyonu olan toplam 144
DKİS hastasına uygulanan SLNB sonuçları geriye dönük olarak incelendi ve
literatür eşliğinde değerlendirildi.

Bulgular: Hastaların yaş ortalaması 53
(36-77) idi. Histopatolojik tanı olguların 103’ünde (%71) iğne işaretli meme
biyopsisi, 34’ünde (%24) eksizyonel biyopsi, 7’sinde ise (% 5) subareolar
eksplorasyon ile konuldu. Histopatolojik incelemede hiçbir sentinal lenf nodu
örneklemesinde invazyon görülmedi. Mikroinvazyonu olan olgulara radyoterapi ve
hormonoterapi, mastektomi yapılan olgulara ise sadece hormonoterapi adjuvan
tedavi olarak uygulandı. Ortalama 48 aylık takiplerinde olgularda aksiller
rekürrens saptanmadı.

Sonuç: DKİS saptanan hastalarda aksiller
metastaz oldukça düşük oranda (<%1) saptandığı için aksiller lenf nodu
örneklemesi bu hastaların hepsinde rutin olarak yapılmamalıdır. Mikroinvaziv
odağa sahip veya mastektomi yapılma endikasyonu bulunan hastalarda örnekleme
SLNB şeklinde yapılarak aksiller diseksiyonun olası morbiditelerinden kaçınılabilinir.

Keywords

Duktal Karsinoma in Situ, Sentinel Lenf Nodu Biyopsisi, Meme Kanseri

References

• Referans1 Klauber-DeMore N, Tan LK, Liberman L, et al. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma- in-situ with microinvasion? Ann Surg Oncol 2000;7:636-42.
• Referans2 Silverstein MJ, Waisman JR, Gamagami P, et al. Intraductal carcinoma of the breast (208 cases). Clinical factors influencing treatment choice. Cancer 1990;66:102-8.
• Referans3 Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma In situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer I 2010;102:170–8. 

• Referans4 Nicholson S, Hanby A, Clements K, et al. Variations in the manage- ment of the axilla in screen-detected ductal carcinoma in situ: evidence from the UK NHS breast screening programme audit of screen detected DCIS. Eur J Surg Oncol 2015;41:86–93.
• Referans5 Chang WC, Hsu HH, Yu JC, et al. Underestimation of invasive lesions in patients with ductal carcinoma in situ of the breast diagnosed by ultrasound-guided biopsy: a comparison between patients with and without HER2/neu overexpression. Eur J Radiol 2014;83:935–41. 

• Referans6 Liu CQ, Guo Y, Shi JY, Sheng Y. Late morbidity associated with a tumour- negative sentinel lymph node biopsy in primary breast cancer patients: a systematic review. Eur J Cancer 2009;45:1560–8. Referans7 Zetterlund L, Stemme S, Arnrup H, de Boniface J. Incidence of and risk factors for sentinel lymph node metastasis in patients with a postoperative diagnosis of ductal carcinoma in situ. Br J Surg 2014;101:488-94. Referans8. Intra M, Rotmensz N, Veronesi P, et al. Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European Institute of Oncology on 854 patients in 10 years. Ann Surg 2008;247:315-9.
• Referans9. Sener SF, Winchester DJ, Martz CH, et al. Lymphedema after sentinel lympha- denectomy for breast carcinoma. Cancer 2001;92:748-52.
• Referans10. Gartner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA 2009;302:1985-92.
• Referans11. Hayes SC, Johansson K, Stout NL, et al. Upper-body morbidity after breast cancer: incidence and evidence for evaluation, prevention, and management within a prospective surveillance model of care. Cancer 2012;118(8 Suppl):2237-49